To compare the 1-hour post-load glucose (1h-PG) value of an Oral Glucose Tolerance Test (OGTT) with the Metabolic Syndrome (MetS) and the Finish Diabetes Risk Score (FINDRISC) in patients with impaired fasting glucose (IFG) to predict T2DM. A cohort study conducted in patients addressed at a general hospital in Lima-Perú. Subjects with IFG performed an OGTT were followed up to seven years for T2DM development. The exposures variables were 1h-PG ≥ 155mg/dL, MetS, and a FINDRISC score ≥ 13 points, and the presence of T2DM was the outcome. The relative risk (RR), confidential interval (CI), and area under the curve (AUROC) were also estimated. Among 324 subjects with IFG, 218 completed the 7-years-follow-up. The mean age was 56.2 ±11.5 years-old, 64.0% were female and 63.8% were overweigh/obese. 36.8% had 1h-PG ≥ 155mg/dL and normal glucose tolerance (NGT), 66.8% had MetS and 64.5% FINDRISC ≥ 13 points. After 7 years, 21.1% of participants developed T2DM, 68.8% of them with 1h-PG ≥ 155mg/dL (p< 0.001), 62.2% with MetS (p= 0.013), and 67.9% with FINDRISC ≥ 13 (p= 0.68). After adjusting by age, sex and BMI, the RR were 3.52 (1.64-7.54; 95%CI), 1.81 (0.96-3.38; 95%CI) and 1.17 (0.51-2.70; 95%CI), for each exposure-variable, respectively. Also, the AUROC were 0.72 (0.60-0.83), 0.63 (0.51-0.75), and 0.51 (0.38-0.63) (p= 0.01), respectively. By performing an OGTT in IFG patients, an 1h-PG ≥ 155 mg/dL value may be helpful to predict T2DM at 7 years better than the use of MetS or FINDRISC score.